Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis

Fig. 3

Anti-PCSK9 significantly decrease circulating cholesterol without alleviating EAE symptoms. A Quantification of circulating tchol, B LDLc and C HDLc of anti-PCSK9 treated mice versus PBS control group (mean ± SD, n = 3 mice). Data are representative of two experiments. Tchol, LDLc and HDLc levels were measured before anti-PCSK9 injection and 9 days after the first anti-PCSK9 injection D Clinical scores of EAE in immunized mice treated with anti-PCSK9 or PBS control (mean ± SEM, n = 7 mice). E Disease free activity between mice treated with anti-PCSK9 or PBS. F Flow cytometry analysis of the total proportion (%) of the leukocyte (viable CD45+), lymphocyte T (CD3+) and lymphocyte T CD4+ (CD4+) in the CNS 14 days after EAE immunization (mean ± SD; n = 4 mice). Data are representative of two experiments. G Histopathological staining and quantifications of spinal cord sections at day 16 post-immunization for cellular infiltration (H&E) of non-immunized (NI) or immunized WT mice treated with PBS as control or with anti-PCSK9. Five sections per mouse were quantified (n = 3). Scale bars 500 µm (top panels), 100 µm (bottom panels). p < 0.05, p < 0.01, NS, not significant; p values were determined by unpaired Student’s t test (AC and G), and a Mann–Whitney U test (D) and a two-way ANOVA with Sidak’s post hoc test (F). AUC were compared by Mann–Whitney test (E)

Back to article page